Improta Giuseppina, Zupa Angela, Possidente Luciana, Tartarone Alfredo, Pedicini Piernicola, Nappi Antonio, Molinari Sergio, Fraggetta Filippo, Vita Giulia
Laboratory of Clinical Research and Molecular Diagnostics, IRCCS-CROB Hospital, Rionero In Vulture, Potenza;
Oncol Lett. 2013 May;5(5):1741-1743. doi: 10.3892/ol.2013.1255. Epub 2013 Mar 14.
Evaluation of the mutational status of KRAS is a crucial step for the correct therapeutic approach in treating advanced colorectal cancer as the identification of wild-type KRAS tumors leads to more specific and less toxic treatments for patients. Although several studies have highlighted the differences between primary and metastatic tumors, the possibility of two or more mutations in the same codon has seldom been reported. The present study reports an additional case of an advanced adenocarcinoma of the colon showing two somatic mutations (p.G12D and p.G12V) in the same codon (codon 12) of exon 2 of the KRAS gene, thus supporting the possibility of two differing clonal origins of the tumor. Although the clinical significance of multiple mutations remains unknown at present, based on the limited data available in the literature, this rare event appears to be associated with a more aggressive disease, as in the present case. This case report demonstrates the existence of intratumoral heterogeneity and the coexistence of distinct clones within a tumor that may have profound clinical implications for disease progression and therapeutic responses.
评估KRAS的突变状态是晚期结直肠癌正确治疗方法的关键步骤,因为野生型KRAS肿瘤的鉴定可为患者带来更具特异性且毒性更小的治疗。尽管多项研究强调了原发性肿瘤和转移性肿瘤之间的差异,但同一密码子出现两个或更多突变的可能性鲜有报道。本研究报告了另一例晚期结肠腺癌病例,该病例在KRAS基因第2外显子的同一密码子(密码子12)处显示出两个体细胞突变(p.G12D和p.G12V),从而支持了肿瘤存在两种不同克隆起源的可能性。尽管目前多个突变的临床意义尚不清楚,但根据文献中的有限数据,这种罕见事件似乎与更具侵袭性的疾病有关,就像本病例一样。本病例报告证明了肿瘤内异质性以及肿瘤内不同克隆的共存,这可能对疾病进展和治疗反应具有深远的临床意义。